Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Liraglutide in Obese Adults With Genetic Mutations
NCT02082496Phase 2Completed
- Sponsor
- University of Copenhagen
- Start
- Jun 2014
- Primary completion
- Apr 2016
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 2, open-label trial of liraglutide in obesity, sponsored by University of Copenhagen. Primary endpoint: Insulin levels in response to GLP-1 RA treatment at 4 months. Started Jun 2014; status: completed.
02
Drugs
03
Conditions
obesity
Beyond the preview
Go deeper on NCT02082496.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02082496.